What Optellum Announced About the NIHR Funded SWIFT LUNG NHS Trial
Optellum said on 15 June 2026 that it had been awarded funding by the National Institute for Health and Care Research through its Invention for Innovation programme for a trial named SWIFT LUNG. The company describes it as a prospective, stepped-wedge clinical trial running across multiple NHS sites in England and Scotland over three years, naming NHS Greater Glasgow and Clyde, NHS Highland and Oxford University Hospitals. Optellum says the trial will measure time to triage, time to diagnosis, clinical effectiveness in reducing diagnostic delays, cost effectiveness, and acceptability and implementation, as well as the ability to distinguish benign from malignant nodules. The announcement names a chief investigator at NHS Greater Glasgow and Clyde and quotes clinicians at the participating sites. No funding amount is stated and no results exist yet.
Why the Optellum SWIFT LUNG Trial Matters to Health System Buyers
The design is the story. A stepped-wedge trial switches sites over to the new tool at different times, so each site acts as its own comparison, which is about as close to a fair test as a hospital rollout can get. That matters because almost every AI result a buyer is shown is a before-and-after at one site, where the staff knew the tool was being watched. It also matters who is paying. A public research funder has no stake in the answer being yes, so an unfavourable result can actually be published. The limits are real too. Three years is a long time, time to diagnosis is a process measure rather than a survival measure, and a result from British lung cancer pathways does not transfer cleanly to a country with different referral rules. Being funded is also not being finished. Trials end early, and nothing here is evidence yet.
Where the Optellum Update Comes From
Optellum is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the Optellum SWIFT LUNG Trial
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start by finding the SWIFT LUNG trial registration, because the registered protocol states the primary outcome and the registration is harder to revise quietly than a press page.
- Then we would ask who holds the publication rights and whether an unfavourable result would be published, since that is the question a public funder usually answers well.
- We would look at how the trial defines time to triage, because a faster hand-off between teams is a different claim from a faster diagnosis for a patient.